Steven Hsu is a Cardiology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
600 N Wolfe St
Baltimore, MD 212870005
Telephone
410-955-7963Provider last certified this registry record 4 Mar 2025.
Clinical trials
- Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure
Sponsor: Johns Hopkins University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20252 payments
- PFIZER INC.Program year20251 payment
- ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
71.2%Beta blocker17.5%Metoprolol Succinate52%Carvedilol48%Part D≥27 patientsAldosterone antagonist (MRA)13.4%Spironolactone69%Eplerenone31%Part D≥28 patients+ 7 more classes in this area
Metabolism & gastrointestinal
17.1%SGLT2 inhibitor14%Jardiance70%Farxiga30%Part D<11 patientsGLP-1 receptor agonist3.1%Ozempic100%Part D<11 patientsBlood & clotting
9.9%Factor Xa inhibitor8.4%Eliquis100%Part D≥17 patientsVitamin K antagonist1.5%Warfarin Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2019–2026 per NIH RePORTER. The latest:
- Myocyte Mechanics of Right Ventricular Contractile Failure in Pulmonary Hypertension due to Heart Failure with Reduced Ejection Fraction
Johns Hopkins University
FY2026$695,316R01HL172830 - Myocyte Mechanics of Right Ventricular Contractile Failure in Pulmonary Hypertension due to Heart Failure with Reduced Ejection Fraction
Johns Hopkins University
FY2025$709,506R01HL172830 - Myocyte Mechanics of Right Ventricular Contractile Failure in Pulmonary Hypertension due to Heart Failure with Reduced Ejection Fraction
Johns Hopkins University
FY2024$548,121R01HL172830
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”